Eisai and MSD submit Japan application for Lenvima plus Welireg in advanced renal cell carcinoma, backed by Phase III LITESPARK-011 data showing significant PFS improvement.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Eisai Co., Ltd. and MSD K.K. have submitted a regulatory application in Japan seeking approval for an additional dosing regimen of Lenvima (lenvatinib) in combination with Welireg (belzutifan) for patients with unresectable or metastatic renal cell carcinoma (RCC) that has progressed following prior therapy.
The filing is supported by results from the Phase III LITESPARK-011 trial (NCT04586231), positioning the combination as a potential new treatment option for patients whose disease has progressed after anti–PD-1/PD-L1 therapies.
In the LITESPARK-011 study, the combination of lenvatinib and belzutifan achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 30% compared with cabozantinib (HR=0.70; p=0.00007).
Median PFS reached 14.8 months with the combination versus 10.7 months with cabozantinib. A favorable trend in overall survival (OS) was also observed, with median OS of 34.9 months compared to 27.6 months, although this endpoint has not yet reached statistical significance.
The combination further improved objective response rate (ORR), achieving 52.6% versus 39.6% with cabozantinib, alongside a longer duration of response (23.0 months vs 12.3 months).
The safety findings were consistent with the established profiles of each agent. Grade ≥3 treatment-related adverse events occurred in 71.6% of patients receiving the combination compared to 65.8% with cabozantinib.
Treatment discontinuation rates were similar between groups (11.1% vs 11.3%), with no new safety signals identified. Serious adverse events and treatment-related deaths were slightly higher in the combination arm but remained within expected ranges.
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that suppresses angiogenesis and tumor proliferation pathways, while belzutifan is a first-in-class HIF-2α inhibitor that disrupts hypoxia-driven tumor survival mechanisms.
The combination is designed to simultaneously inhibit tumor blood vessel formation and adaptive responses to low-oxygen environments, offering a complementary mechanism of action in RCC.
Lenvatinib is already approved in Japan in combination with pembrolizumab as a first-line treatment for advanced RCC, while belzutifan is approved for RCC following chemotherapy.
In parallel, supplemental applications for the same combination have been accepted by the U.S. FDA, with a target action date of October 4, 2026, highlighting the global regulatory momentum behind this regimen.
Eisai and MSD continue to collaborate on the co-development and commercialization of lenvatinib-based regimens, aiming to expand treatment options for patients with advanced cancers.
Renal cell carcinoma accounts for approximately 85% of kidney cancers and remains associated with poor outcomes in advanced stages, with five-year survival rates as low as 27–28% in stage IV disease.
The Lenvima–Welireg combination may offer a new therapeutic option for patients with disease progression after immunotherapy, addressing a significant unmet need in this setting.
References
Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy, 27 March 2026, No.26-21
A Study of Belzutifan (MK-6482) in Combination with Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011), ClinicalTrials.gov ID NCT04586231, https://clinicaltrials.gov/study/NCT04586231
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.